The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice

Rolin, Bidda; O. Larsen, Marianne; F. Gotfredsen, C.; F. Deacon, Carolyn; D. Carr, Richard; Wilken, Michael; Bjerre Knudsen, Lotte

doi:10.1152/ajpendo.00030.2002

Public

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice

Published in American Journal of Physiology-Endocrinology and Metabolism • Oct 1, 2002

Authors:

Bidda Rolin

Marianne O. Larsen

C. F. Gotfredsen

Abstract

NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1) derivative designed for once daily administration in humans. NN2211 dose dependently reduced the glycemic levels in ob/ob mice, with antihyperglycemic activity still evident 24 h postdose. Apart from an initial reduction i...

View

Paywalled

Subject

Internal medicine

Endocrinology

Glycemic

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions